• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    From Nitinol to Nanotubes: A Materials Science Roundtable

    In Good Repair: Trauma Technologies Under Review

    Anxious Undertones: A Review of 2019

    Automated Analysis Advantages for Part Validation

    Tried and True Metalworking
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

    TriMed Closes Out FDA Warning Letter

    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Tyber Medical Opens $8M Office and Manufacturing Facility
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    TriMed Closes Out FDA Warning Letter

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

    3D-Printed Graftless Bone Transplants Go to Clinical Trials
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?

    New Exoskeleton Shoulders Rehab Burden for Stroke Patients

    Repairing Knee Cartilage Defects with the Patient's Own Cells

    Compamed 2019 Preview Report
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Orthopedic Innovation Pty. Ltd.

    Tecomet

    Orchid Orthopedic Solutions

    Hammill Medical

    Edge International/Supra Alloys
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Breaking News

    SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell Injection

    Data shows significant improvement in clinically relevant endpoints.

     SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell Injection
    Related CONTENT
    • Lipogems Receives FDA Clearance For Microfragmented Adipose Tissue System
    • Bright Horizons: Highlighting Six Orthopedic Technology Companies to Watch
    • Robotics Revolution
    • 2. DePuy Synthes
    • 1. Stryker Corp.
    Business Wire01.08.19
    SpinalCyte LLC, a regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell, announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD).
     
    The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54 percent of the treatment arm patients met all three endpoints as compared to only 17 percent with the placebo (p=0.0003). Over 84 percent of patients in the treatment group of CybroCell or CybroCell with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25 percent for the placebo saline injection.
     
    Analyzed individually, 83 percent of spinal discs that were injected with CybroCell had an increase or no change in disc height compared to 25 percent of saline injected discs. The 12-month MRI data from the landmark Phase 1/Phase 2 trial were analyzed for 17 patients by an independent radiological expert.
     
    “Verification of structural improvements via MRI at six and 12 months strongly suggests that we are inducing a biological cascade of events associated with the induction of a regenerative process in the patient,” said Jesus Perez, M.D., principal investigator of the clinical trial. “Based on the clinical observations, imaging studies and patient testimonies, I believe that CybroCell is a breakthrough in the treatment of DDD.”
     
    As previously reported, after six and 12 months, more than 90 percent of the treatment group had over a 10-point reduction in Oswestry Disability Index (ODI) and 100 percent had improvement in Visual Analogue Scale (VAS). On average, treatment group patients showed a 59 percent improvement in ODI scores, compared to the 22 percent improvement in the placebo group.
     
    “The MRI image study demonstrates that a single injection of CybroCell leads to persistent structural and functional improvement in patients with DDD over a year,” said SpinalCyte Chief Scientific Officer Thomas Ichim, Ph.D. “To my knowledge, the pain and MRI data are clearly superior to all other reported cell therapy trial data for DDD. Developing solutions which target and treat the source of chronic pain for patients with DDD, a population which today accounts for about 50 percent of prescription opioid usage, has implications in combating the opioid epidemic.”
     
    SpinalCyte’s Phase 1/Phase 2 clinical trial is the first allogeneic use of fibroblasts outside of skin conditions. CybroCell is based on research showing that skin derived cells are capable of healing the disc as previously reported in The Spine Journal.
     
    “There are limited options to treat the pain in patients with DDD and no treatments that can regrow the spinal disc,” said SpinalCyte CEO Pete O’Heeron. “With the positive 12-month data from our trial, SpinalCyte is positioned at the forefront of this emerging sector of fibroblast-based cell therapies. In contrast to stem cells, which are difficult and costly to procure and develop into a drug, CybroCell uses fibroblasts which are found in large numbers and are already approved by the FDA for treatment of skin conditions. Our proprietary technology also holds promise for additional degenerative ailments including disc degeneration, cancer, diabetes, liver failure and heart failure.”
     
    Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85 percent of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
     
    CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients who were injected with CybroCell had sustained improvement in pain relief and increased back mobility.
     

    Based in Houston, Texas, SpinalCyte LLC is a regenerative medicine company developing a solution for spinal disc regeneration using human dermal fibroblasts. Currently, SpinalCyte holds 35 U.S. and international issued patents and has filed for an additional 41 patents pending. SpinalCyte holds 110 U.S. and international patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy.
    Related Searches
    • stem cells
    • imaging
    • patient
    • technology
    Suggested For You
    Material Matters: New Offerings for Orthopedic Technologies Material Matters: New Offerings for Orthopedic Technologies
    Data Monitoring Committees: Making DMCs Work for Your Study Data Monitoring Committees: Making DMCs Work for Your Study
    FDA Plans to Modernize 510(k) Program FDA Plans to Modernize 510(k) Program
    SpinalCyte Announces New International Patents SpinalCyte Announces New International Patents
    SpinalCyte Announces Positive 12-Month Pain Data From Trial for Degenerative Disc Disease SpinalCyte Announces Positive 12-Month Pain Data From Trial for Degenerative Disc Disease
    Zimmer Biomet Spine Announces FDA Approval of Mobi-C Cervical Disc Labeling Extension Zimmer Biomet Spine Announces FDA Approval of Mobi-C Cervical Disc Labeling Extension
    Do New Structures Redefine Do New Structures Redefine 'Material'?
    SpinalCyte LLC Issued New U.S. Patent SpinalCyte LLC Issued New U.S. Patent
    1. Stryker Corp. 1. Stryker Corp.
    2. DePuy Synthes 2. DePuy Synthes
    Robotics Revolution Robotics Revolution
    Bright Horizons: Highlighting Six Orthopedic Technology Companies to Watch Bright Horizons: Highlighting Six Orthopedic Technology Companies to Watch
    Lipogems Receives FDA Clearance For Microfragmented Adipose Tissue System Lipogems Receives FDA Clearance For Microfragmented Adipose Tissue System

    Related Breaking News

    • Biologics
      Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

      Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

      The increasing prevalence of myeloma is leading to a rise in the execution of bone marrow transplantation procedures, study concludes.
      Persistence Market Research 12.12.19

    • Extremities
      TriMed Closes Out FDA Warning Letter

      TriMed Closes Out FDA Warning Letter

      Receipt of closeout letter signals the completion of a 24-month initiative to expand and enhance quality management systems.
      Business Wire 12.11.19

    • Extremities
      FDA OKs Shoulder Innovations

      FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System

      The new InSet Plus glenoids feature an angled articular surface.
      PR Newswire 12.10.19


    • Trauma/Sports
      OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

      OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

      Trauma application added to universal PhantomMSK platform; one platform with use across a variety of procedures.
      OrthoGrid 12.10.19

    • Tyber Medical Opens $8M Office and Manufacturing Facility

      Tyber Medical Opens $8M Office and Manufacturing Facility

      Creates about 30 additional jobs for Lehigh Valley's second-fastest growing company.
      PR Newswire 12.10.19

    • Extremities | Software & Quality
      FDA OKs Shoulder Surgery 3D Planner & Positioner

      FDA OKs Shoulder Surgery 3D Planner & Positioner

      Intuitive, surgeon-driven software provides 3D pre-operative planning and 3D positioners for intra-operative positioning.
      PR Newswire 12.10.19


    • Spine/Neurology
      Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

      Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

      Patient enrollment in this U.S. study will now continue through completion of 60 total subjects.
      PR Newswire 12.10.19

    • Spine/Neurology
      InVivo Therapeutics Attains 25 Percent Enrollment in Spinal Cord Injury Study

      InVivo Therapeutics Attains 25 Percent Enrollment in Spinal Cord Injury Study

      Fourteen sites currently are open for patient enrollment.
      Business Wire 12.09.19

    • BioPrax Biofilm Disruption Device Granted FDA Breakthrough Device Designation

      BioPrax Biofilm Disruption Device Granted FDA Breakthrough Device Designation

      Product is designed to help eliminate biofilm infections on prosthetic knee implants during early intervention procedures.
      PR Newswire 12.09.19


    • Spine/Neurology
      Orthofix Appoints New Spine Business Leader

      Orthofix Appoints New Spine Business Leader

      Kevin Kenny was previously VP of U.S. sales for Spine and Biologics at Medtronic.
      Business Wire 12.05.19

    • Packaging & Sterilization
      Viant to Halt EtO Sterilization at Michigan Plant by End of Year

      Viant to Halt EtO Sterilization at Michigan Plant by End of Year

      EGLE had been investigating over the past year and issued Viant several violations for inadequate capture and control of ethylene oxide emissions.
      Michigan Department of Environment, Great Lakes, and Energy (EGLE) 12.04.19

    • Spine/Neurology
      Synaptive Medical

      Synaptive Medical's Modus V Expands Into Spine Market

      Modus V’s robotic arm moves automatically based on the positions of tracked surgical instruments.
      Business Wire 12.04.19

    • 3-D Printing/Additive Mfg. | Biologics | Materials
      3D-Printed Graftless Bone Transplants Go to Clinical Trials

      3D-Printed Graftless Bone Transplants Go to Clinical Trials

      ADAM is piloting the use of ceramics and polymer in 3D-printed bone implants, able to be produced at commodity prices.
      PR Newswire 12.04.19

    • Extremities
      CrossRoads Extremity Systems Acquires Implant Systems from Surgical Frontiers

      CrossRoads Extremity Systems Acquires Implant Systems from Surgical Frontiers

      The add-on acquisition furthers CrossRoads' strategy to build a market-leading company in the high-growth orthopedic extremities sector.
      PR Newswire 12.04.19

    • Spine/Neurology
      Micro Spine Implant Could Restore Standing and Walking

      Micro Spine Implant Could Restore Standing and Walking

      Hair-like electrical wires send electrical signals to trigger networks that already know how to do the hard work.
      University of Alberta Faculty of Medicine & Dentistry 12.03.19


    Breaking News
    • Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    • TriMed Closes Out FDA Warning Letter
    • FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    • OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    • Tyber Medical Opens $8M Office and Manufacturing Facility
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • From Nitinol to Nanotubes: A Materials Science Roundtable
    • In Good Repair: Trauma Technologies Under Review
    • Anxious Undertones: A Review of 2019
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Arkema: Bostik Acquires Danish Company LIP
    Axalta Adds New Epoxy Primer to Tufcote Liquid Industrial Coatings Portfolio
    Chromaflo Technologies Promotes Sergio Duenas to Country Manager of Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MedStar Health and Cleveland Clinic Innovations Awarded Grant
    3M to Sell Drug Delivery Business for $650M
    First U.S. Patient Implanted With Axonics' Sacral Neuromodulation System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Arctoris Opens Oxford R&D Facility
    Almac Group, Exostar Collaborate on IRT Experience
    Northwest Biotherapeutics Expands Management Team
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Prada & L’Oréal Sign Long-Term Licensing Deal
    Happi

    Latest Breaking News From Happi

    Treasuring Textured Hair
    Pacifica 'Drops' Skin Care Into Ingestible
    Skinnygirl Expands Into Supplements
    Ink World

    Latest Breaking News From Ink World

    Ripon Printers Adds Ricoh Pro C9210
    Canon Solutions America Powers University of Notre Dame Athletics' Printing Capabilities
    Worldwide Large Format Printer Shipments Down Slightly in 3Q 2019: IDC
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    GSE products provide quality assurance for Pharmalabel
    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    DuPont to Acquire Osmosis Specialist
    Nice-Pak to Expand in Indiana
    Hospeco Launches Compact Fem Hy Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    TriMed Closes Out FDA Warning Letter
    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    3D Printing Materials Market to Grow at 23.9% CAGR Through 2025: GVR
    Kyocera, TactoTek Collaborate on Injection Molded Structural Electronics Solutions
    Toray Opens R&D Innovation Center for the Future

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.